Related Experiment Video
Updated: Aug 22, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
Roelien H Enting1, Alexis Demopoulos, Lisa M DeAngelis
1Department of Neurology, University Hospital, Groningen, The Netherlands.
Abstract:
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.

